Key Points
- Beth Hecht sold 16,667 Xeris (NASDAQ:XERS) shares on April 1 at an average price of $5.99 for ~$99,835 under a pre-arranged Rule 10b5-1 plan, lowering her holding to 1,209,840 shares (a 1.36% decrease).
- She executed identical 16,667-share sales on March 2 (at $6.25) and Feb 2 (at $7.45), indicating a sequence of monthly disposals at decreasing prices.
- Xeris posted a quarterly EPS beat ($0.06 vs. $0.03 consensus) with revenue roughly in line, has a market cap near $1.04 billion, a consensus rating of Moderate Buy with a $10.80 target, and has seen sizable position increases by institutional investors such as Goldman Sachs and Millennium.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.99, for a total transaction of $99,835.33. Following the transaction, the insider directly owned 1,209,840 shares in the company, valued at approximately $7,246,941.60. The trade was a 1.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Beth Hecht also recently made the following trade(s):
- On Monday, March 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.25, for a total transaction of $104,168.75.
- On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.45, for a total transaction of $124,169.15.
Xeris Biopharma Price Performance
Shares of XERS stock opened at $6.04 on Friday. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.57. The company has a market capitalization of $1.04 billion, a PE ratio of -603.40 and a beta of 0.77. The firm's 50-day moving average is $6.33 and its two-hundred day moving average is $7.29. Xeris Biopharma Holdings, Inc. has a 12 month low of $3.81 and a 12 month high of $10.08.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $85.81 million during the quarter, compared to analysts' expectations of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. Analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.
Hedge Funds Weigh In On Xeris Biopharma
Several large investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company's stock valued at $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock worth $461,000 after purchasing an additional 3,594 shares in the last quarter. Millennium Management LLC boosted its position in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after buying an additional 369,420 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after buying an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP acquired a new stake in shares of Xeris Biopharma in the first quarter valued at $170,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
XERS has been the subject of several analyst reports. Weiss Ratings upgraded Xeris Biopharma from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, March 4th. Barclays assumed coverage on Xeris Biopharma in a research report on Monday, December 8th. They issued an "overweight" rating and a $9.00 target price on the stock. Wall Street Zen raised Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.80.
Check Out Our Latest Analysis on XERS
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
